Analysis of circulating tumor cells in patients with hepatocellular carcinoma recurrence following liver transplantation

2018 ◽  
Vol 66 (5) ◽  
pp. 1.6-6 ◽  
Author(s):  
Shaoping Wang ◽  
Yujian Zheng ◽  
Jun Liu ◽  
Feng Huo ◽  
Jie Zhou
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Tumor Diameter ◽  
Multicenter Studies ◽  
Patients With Cancer ◽  
T Stage ◽  
Hepatocellular Carcinoma Recurrence ◽  
Hcc Recurrence

Although studies have shown that detection of peripheral circulating tumor cells (CTCs) is an important tool for monitoring prognosis and therapeutic response in patients with cancer, few studies have analyzed their role in patients with hepatocellular carcinoma (HCC) following liver transplantation (LTx). The present study examined whether CTC levels were associated with HCC recurrence in patients with HCC after LTx. This prospective study included 47 patients who received LTx between October 2014 and May 2016 and who underwent analysis for peripheral CTCs at least twice using the CanPatrol system. Baseline Edmondson stage, T stage, accumulated tumor diameter, microvascular cancer embolus, and alpha-fetoprotein (AFP) levels were greater in patients with recurrence (all p<0.05). In addition, 70.2% of patients with HCC were CTC-positive. Although the proportion of CTC subtypes changes following LTx and over the follow-up period with increased epithelial and interstitial CTC levels, no significant associations were observed between change in total CTCs or CTC subtype and HCC recurrence (all p>0.05). In conclusion, baseline Edmondson stage, T stage, accumulated tumor diameter, microvascular cancer embolus, and AFP levels may be predictive of HCC recurrence following LTx; however, CTC levels and subtypes were not. Further large, multicenter studies are necessary to confirm these results.

Role of Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation

2016 ◽  
Vol 26 (4) ◽  
pp. 348-355 ◽  
Author(s):  
Nicola de’Angelis ◽  
Filippo Landi ◽  
Marco Nencioni ◽  
Anais Palen ◽  
Eylon Lahat ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
Survival Rates ◽  
Early Recurrence ◽  
Best Supportive Care ◽  
Curative Intent ◽  
Sorafenib Group ◽  
Hepatocellular Carcinoma Recurrence ◽  
Retrospective Comparative Study ◽  
Hcc Recurrence

Context: The management of hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT) is challenging, especially if it is not treatable by surgery or embolization. Objectives: The present study aims to compare the survival rates of liver transplanted patients receiving sorafenib or best supportive care (BSC) for HCC recurrence not amenable to curative intent treatments. Design: This is a retrospective comparative study on a prospectively maintained database. Participants: Liver transplanted patients with untreatable HCC recurrence receiving BSC (n = 18) until 2007 or sorafenib (n = 15) thereafter were compared. Results: No group difference was observed for demographic characteristics at the time of transplantation and at the time of HCC recurrence. On the explant pathology of the native liver, 81.2% patients were classified within the Milan criteria, and 53.1% presented with microvascular invasion. Hepatocellular carcinoma recurrence was diagnosed 17.8 months (standard deviation: 14.5) after LT, with 17 (53.1%) patients presenting with early recurrence (≤12 months). The 1-year survival from untreatable progression of HCC recurrence was 23.9% for the BSC and 60% for the sorafenib group ( P = .002). The type of treatment (sorafenib vs BSC) was the sole independent predictor of survival (hazard ratio: 2.98; 95% confidence interval: 1.09-8.1; P = .033). In the sorafenib group, 8 (53.3%) patients required dose reduction, and 2 (13.3%) patients discontinued the treatment due to intolerable side effects. Conclusion: Sorafenib improves survival and is superior to the BSC in cases of untreatable posttransplant hepatocellular carcinoma recurrence.

scholarly journals Analysis of preoperative circulating tumor cells for recurrence in patients with hepatocellular carcinoma after liver transplantation

2020 ◽  
Vol 8 (17) ◽  
pp. 1067-1067
Author(s):  
Zhitao Chen ◽  
Xiaohong Lin ◽  
Chuanbao Chen ◽  
Yinghua Chen ◽  
Qiang Zhao ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
Tumor Cells ◽  
Circulating Tumor Cells

scholarly journals Oncological Evaluation Using Circulating Tumor Cells and PET-CT of Patients with Hepatocellular Carcinoma Undergoing Liver Transplantation

HPB ◽  
2021 ◽  
Vol 23 ◽  
pp. S949-S950
Author(s):  
D. Ferreras ◽  
P. Cascales-Campos ◽  
F. Alconchel-Gago ◽  
F. Villalba-López ◽  
L.F. Saenz-Mateos ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Pet Ct

Left adrenal hepatocellular carcinoma recurrence in liver transplanted patient

2019 ◽  
Vol 8 (2) ◽  
Author(s):  
Alessandro Parente
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
Liver Cirrhosis ◽  
Adrenal Gland ◽  
Blood Test ◽  
Clinical Signs ◽  
Left Adrenal Gland ◽  
Hepatocellular Carcinoma Recurrence ◽  
Hcc Recurrence ◽  
Regional Treatment

Hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT) has been reported in less than 20% of patients fulfilling Milan Criteria. Mostly, it occurs within the liver, lungs, lymph nodes, bones and brain. A 45 years old Caucasian man affected by HCV-related liver cirrhosis with HCC, who underwent several multi-modal treatments, including hepatic resection, liver transplantation and loco regional treatment presented in our Department with an unusual mass within the left adrenal gland. No clinical signs were associated. However, considering his blood test and the high risk of HCC recurrence, a mini-invasive left surrenalectomy was performed showing HCC metastases in the left adrenal gland. This case shows that even extremely rare sites of HCC metastases have to be investigated, especially if, despite all available treatments, still persist a clinical or laboratory suspect.

scholarly journals Clearance of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Undergoing Surgical Resection or Liver Transplantation

Cancers ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 2476
Author(s):  
Víctor Amado ◽  
Sandra González-Rubio ◽  
Javier Zamora ◽  
Rafael Alejandre ◽  
María Lola Espejo-Cruz ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
Chronic Hepatitis ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Surgical Resection ◽  
Tumor Recurrence ◽  
Surrogate Marker ◽  
Blood Samples ◽  
Prospective Pilot Study

Background: In patients with hepatocellular carcinoma (HCC), a complete clearance of circulating tumor cells (CTCs) early after liver transplantation (LT) or surgical resection (LR) could prevent tumor recurrence. Methods: prospective pilot study including patients with HCC who underwent LR or LT from September 2017 to May 2020. Enumeration of CTCs was performed in peripheral blood samples (7 mL) using the Isoflux® system (Fluxion Biosciences) immediately before surgery, at post-operative day 5 and at day 30. A clinically relevant number of CTCs was defined as >30 CTCs/sample. Results: 41 HCC patients were included (mean age 58.7 ± 6.3; 82.9% male). LR was performed in 10 patients (24.4%) and 31 patients (75.6%) underwent LT. The main etiology of liver disease was chronic hepatitis C (31.7%). Patients undergoing LR and LT were similar in terms of preoperative CTC count (p = 0.99), but clearance of CTCs within the first month was more pronounced in the LT group. Clusters of CTCs at baseline were associated with incomplete clearance of CTCs at day 30 (54.2% vs. 11.8%, p = 0.005), which in turn impacted negatively on survival (p = 0.038). Conclusion: Incomplete clearance of CTCs after surgery could be a surrogate marker of HCC aggressiveness.

TLR9-1486C/T polymorphism is associated with hepatocellular carcinoma recurrence after liver transplantation

2019 ◽  
Vol 13 (12) ◽  
pp. 995-1004 ◽  
Author(s):  
Sara de la Fuente ◽  
María-Jesús Citores ◽  
José-Luis Lucena ◽  
Pablo Muñoz ◽  
Valentín Cuervas-Mons
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
Real Time Pcr ◽  
Tumor Recurrence ◽  
Post Transplant ◽  
Explanted Liver ◽  
Increased Risk ◽  
Poorly Differentiated ◽  
Hepatocellular Carcinoma Recurrence ◽  
Hcc Recurrence

Aim: To determine whether TLR9 polymorphisms are associated with tumor recurrence after liver transplantation for hepatocellular carcinoma (HCC). Patients & methods: All patients who underwent liver transplantation, and had viable HCC in the explanted liver were included. TLR9-1237C/T and -1486C/T polymorphisms were analyzed by real-time PCR and melting curves analysis. Results: 20 of 159 patients (12.6%) developed post-transplant HCC recurrence. Tumors exceeding Milan criteria, moderately-to-poorly differentiated tumors and microvascular invasion on explants, and pretransplant α-fetoprotein level (all p < 0.01) were associated with an increased risk, while TLR9-1486TT genotype was associated with a decreased risk of HCC recurrence (p = 0.03). Conclusion:  TLR9-1486C/T might help to preoperatively identify patients at low risk of post-transplant HCC recurrence.

scholarly journals Circulating Tumor Cells in Hepatocellular Carcinoma: A Comprehensive Review and Critical Appraisal

2021 ◽  
Vol 22 (23) ◽  
pp. 13073
Author(s):  
María Lola Espejo-Cruz ◽  
Sandra González-Rubio ◽  
Javier Zamora-Olaya ◽  
Víctor Amado-Torres ◽  
Rafael Alejandre ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Ex Vivo ◽  
Dynamic Assessment ◽  
Qualitative Assessment ◽  
Current Evidence ◽  
Tumor Surveillance ◽  
Hcc Recurrence

Hepatocellular carcinoma (HCC) is the fifth most common neoplasm and a major cause of cancer-related death worldwide. There is no ideal biomarker allowing early diagnosis of HCC and tumor surveillance in patients receiving therapy. Liquid biopsy, and particularly circulating tumor cells (CTCs), have emerged as a useful tool for diagnosis and monitoring therapeutic responses in different tumors. In the present manuscript, we evaluate the current evidence supporting the quantitative and qualitative assessment of CTCs as potential biomarkers of HCC, as well as technical aspects related to isolation, identification, and classification of CTCs. Although the dynamic assessment of CTCs in patients with HCC may aid the decision-making process, there are still many uncertainties and technical caveats to be solved before this methodology has a true impact on clinical practice guidelines. More studies are needed to identify the optimal combination of surface markers, to increase the efficiency of ex-vivo expansion of CTCs, or even to target CTCs as a potential therapeutic strategy to prevent HCC recurrence after surgery or to hamper tumor progression and extrahepatic spreading.

Sign in / Sign up

Export Citation Format

Share Document